Alterity Therapeutics Limited (ATHE) 銘柄情報

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –

– Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale –

– Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions –

– ATH434 Demonstrated a Favorable Safety Profile –

– Webcast Held Yesterday with Access to the Recording Below –

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA).

The topline data showed that ATH434 produced clinically and statistically significant improvement on the modified UMSARS Part I, a functional rating scale that assesses disability on activities of daily living affected in MSA1. On this important clinical measure, ATH434 demonstrated 48% slowing of clinical progression at the 50 mg dose (p=0.03)^ and 29% slowing of clinical progression at the 75 mg dose (p=0.2) at Week 52 when compared with placebo. The 75 mg dose group showed a 62% slowing of progression (p=0.05) at Week 26. In addition to the robust efficacy demonstrated on the UMSARS I, trends of improved motor performance were observed on the Parkinson’s Plus rating scale2 and overall benefit was shown on the Clinical Global Impression of Severity at the 50 mg dose (p=0.009).

Biomarkers were used to evaluate potential drug effect and target engagement. Regarding iron content by MRI, the 50 mg dose reduced iron accumulation in MSA affected brain regions (substantia nigra, putamen, and globus pallidus) and the 75 mg dose reduced iron accumulation in the globus pallidus. The reduced accumulation of iron was significant for the 50 mg dose group at 26 weeks (putamen, P=0.025) and approached statistical significance at 52 weeks (globus pallidus, P=0.08). Trends in preservation of brain volume were observed in the 50 mg and 75 mg groups relative to placebo at both 26 and 52 weeks of treatment.

“We are thrilled that ATH434 has demonstrated significant slowing of clinical progression and an excellent safety profile in this rare, rapidly progressive disease,” said David Stamler, M.D., Chief Executive Officer of Alterity. “Currently, there are no approved treatments that slow the progression of MSA and these results show that ATH434’s targeted iron engagement may truly have a disease modifying effect. The fact that we achieved statistical significance on the UMSARS is extremely meaningful because it assesses the functional areas affected in MSA and is the endpoint needed to support drug approval by the U.S. Food and Drug Administration (FDA). Based on the strength of these Phase 2 data, we look forward to engaging with the FDA as quickly as possible to discuss the path forward for accelerating the development of ATH434 given the tremendous unmet need for treating MSA. We are very grateful for the invaluable contributions of the study participants and the clinical sites who contributed to the study.”

Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Coordinating Investigator for the ATH434-201 Phase 2 study, commented “The findings from the study are compelling because ATH434 appears to have meaningfully slowed MSA progression and stabilized motor function. To date, no treatment has altered the progression of this devastating disease. The slowing of clinical progression in this study, particularly at 50 mg, is impressive. I look forward to continue working with Alterity to bring this therapy to patients, and I know the MSA community welcomes this exciting advancement.”

Dr. Stamler concluded, “We now have evidence that targeting excess labile iron in neurodegenerative disease can be achieved. By redistributing this reactive form of iron that contributes to disease pathogenesis, not only can we target a-synuclein aggregation, but we can also break the vicious cycle underlying disease progression. This has implications for developing disease modifying treatments for orphan diseases such as MSA and Friedreich’s ataxia as well as major neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease.”

Webcast details

The webcast recording can be accessed on the Events and Presentation page of the Company’s website here.

ATH434-201 Topline Data Summary

The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in participants with early-stage MSA. The trial enrolled globally with 23 sites in six countries. The study evaluated the efficacy, safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable movement sensors were employed to evaluate motor activities in an outpatient setting. The study enrolled 77 adults who were randomly assigned to receive one of two dose levels of ATH434 (50mg or 75mg) or placebo. Treatment was administered orally twice-a-day (BID).

ATH434 Efficacy Results (n=61)
The principal efficacy analyses were performed on the modified Intent-to-Treat (mITT) population, which includes enrolled participants who received study drug and had at least one MRI evaluation for brain iron at six months. There were approximately 20 patients per arm in the mITT. Both clinical doses demonstrated improvement relative to placebo over 52 weeks, with the 50 mg dose showing a greater treatment effect. Additional analyses are ongoing to understand the differences between the two groups.

Key Biomarker Endpoint:
On the primary endpoint of iron content by MRI, ATH434 demonstrated reduced or stabilized iron content in key brain regions affected by MSA.

Demonstrated target engagement of ATH434
The 50 mg dose reduced iron accumulation in the substantia nigra, putamen, and globus pallidus The reduced accumulation of iron was significant at 26 weeks (putamen, P=0.025) and approached statistical significance at 52 weeks (globus pallidus, P=0.08)
The 75 mg dose reduced iron accumulation in the globus pallidus
Other biomarkers were used to evaluate potential drug effect and target engagement.

Brain Volume: ATH434 demonstrated a trend in preserving brain volume as compared to placebo at both 50 mg and 75 mg dose levels, as assessed by the MSA atrophy index (MSA-AI)3
NfL: The analysis of neurofilament light chain (NfL) levels in spinal fluid is ongoing
Key Clinical Endpoint: UMSARS Part I
The key secondary endpoint was defined as the change in the Unified MSA Rating Scale Part I (UMSARS I). UMSARS I is a functional rating scale that assesses disability and disease severity in MSA. It is the most meaningful endpoint in the trial, as it is the clinical endpoint of interest to support approval by regulatory authorities such as the FDA.

Placebo treated patients declined by a mean of 4.5 points over 26 weeks and 8.2 points over 52 weeks
The 50 mg dose declined by a mean of 4.3 points over 52 weeks, equivalent to a 48% slowing of clinical progression (p=0.03)
The 75 mg dose declined by a mean of 5.8 points over 52 weeks, equivalent to a 29% slowing of clinical progression (p=0.2)
The 75 mg dose declined by a mean of 1.8 points over 26 weeks equivalent to a 62% slowing of clinical progression (p=0.05)
Both dose groups clearly separated from placebo.
Additional Secondary Endpoints:
Observed trends of improved motor performance support the efficacy of ATH434 in the clinical setting:

Clinical Global Impression of Severity4 (7-point scale, higher score worse) Mean change at 50 mg: -0.81 (p=0.009)Mean change at 75 mg: -0.18 (p=NS)
Parkinson Plus total motor scale: Trends in both dose groups at 26 and 52 weeks with a clinical benefit apparent in multiple domains
Increased activity on wearable sensors in both groups with increases in step count, bouts of walking, total walking time, and standing time
Orthostatic Hypotension Symptom Assessment (patient rated) showed trends favoring benefit in both groups (p=0.13 at 50 mg)
ATH434 Safety Results (n=77)
The safety population includes all enrolled participants who received at least one dose of study drug. Overall, 26 participants received the 50 mg dose, 25 participants received the 75 mg dose, and 26 participants received placebo.

ATH434 was well-tolerated with similar adverse event (AE) rates in ATH434 treatment groups and placebo
Most AEs were mild to moderate in severity
No serious adverse events (SAEs) related to ATH434 were reported
Discontinuations for AEs were similar in the placebo (n=3) and 75 mg dose (n=5) groups and lowest at 50 mg (n=0). None of the AEs leading to discontinuation were related to treatment.
About ATH434

Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce a-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 recently announced positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA. A second Phase 2 open-label 2 Biomarker trial in patients with more advanced MSA is ongoing. ATH434 has been granted Orphan Drug Designation for the treatment of MSA by the U.S. FDA and the European Commission.

About Multiple System Atrophy

Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological

ATHE: They are asleep-on-the-job, Boss!!! (And yet another HUUUUUUUGE-THANKS-A-MUNDO, Homeboy!!!)

ATHE...............................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

Strong hands dude!!!

$7.42 + 160% flipping some now at $7 and high $6s 

Where is everyone still running $5.81+ 100%

athe................................https://stockcharts.com/h-sc/ui?s=athe&p=W&b=5&g=0&id=p86431144783

https://x.com/THIS_TIME_X/status/1884012136411848992

ATHE.......................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783.

ATHE...................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE.............................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE.......................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE......https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE.................................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE.................................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE under $2

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

ATHE...............................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE...................................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

Phase 2 data due at AAN 2024 on April 14, 2024.

ATHE new 52 week low

Moron on ECN MEMX which is more often connected to Schwab, showing a little sellside size at $3.25, could be just some short being a fool trying to manipulate and keep it from breaking out to higher levels,they are most likely could end up getting squeezed out, or sorry they sold,and are just a fool.

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
- ATH434 improved motor performance and general function –

- Webcast to be held this week to discuss new data and recent clinical progress –

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that promising new data on the effect of ATH434 in a Parkinson’s disease primate model was presented at the Future of Parkinson’s Disease Conference 2023 that took place November 30 – December 3, 2023 in Austin, TX, USA.

The poster, entitled, “Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in Hemiparkinsonian Macaques”, was presented by Margaret Bradbury, PhD, Vice President of Research and Nonclinical Development at Alterity and collaborators from Vanderbilt University Medical Center and the Florey Institute of Neuroscience in Melbourne. The presentation demonstrated that ATH434 treatment improved motor performance and general function in monkeys with experimentally induced Parkinson’s disease. The favorable impact on Parkinson’s symptoms was associated with lower iron levels in the area of pathology. In addition, ATH434 treatment increased levels of synaptophysin, a protein marker that reflects functional connections between neurons.

David Stamler, M.D., Chief Executive Officer of Alterity, commented, “These new data are exciting because we have shown for the first time that ATH434 can reduce Parkinson’s symptoms in a higher order animal – the monkey. Importantly, the improvements in motor skills and general functioning that parallel human parkinsonism were associated with reductions in iron in affected brain regions, validating the approach we are using in our ongoing clinical trials. The data from this study improve our ability to predict clinical outcomes and increases our confidence level in our ongoing Phase 2 clinical trials in Multiple System Atrophy, a parkinsonian disorder with similar underlying pathology to Parkinson’s disease.”

The study compared daily oral doses of ATH434 (3 or 10 mg/kg) versus a vehicle (placebo) for 12-14 weeks after parkinsonian symptoms were evident. Monkeys were assessed with the Parkinson Behavior Rating Scale (PBRS) before, during and after dosing. At Week 12, all evaluable ATH434-treated monkeys (n=5) had stable or improving PBRS scores from Baseline to Week 12 whereas two of three vehicle-treated monkeys did not demonstrate improvement or worsened, as expected from the progressive nature of the Parkinson model. The components of the PBRS scale indicate that ATH434 reduced motor impairment and improved general functions such as posture, balance, activity, and gait. Favorable parkinsonian outcomes observed in each of the ATH434-treated monkeys were associated with lower iron in the right substantia nigra. In addition, monkeys with improved scores had higher right dorsal striatal synaptophysin, indicating functional recovery of nerve endings in this critical motor pathway.

The poster presentation can be accessed on the Published Scientific Research section of the Alterity website here.

Webcast details

AUSTRALIA PARTICIPANTS:
Date: Wednesday, 6 December 2023
Time: 9:00 a.m. AEDT (Sydney/Melbourne)


UNITED STATES PARTICIPANTS:
Date: Tuesday, 5 December 2023
Time: 2:00 p.m. Pacific Time
5:00 p.m. Eastern Time
Register for the Zoom webcast:
https://us02web.zoom.us/webinar/register/WN_9Lv1OWMtSSSqdJrRsKRiTA#/registration
Registration is required and dial in details will be sent directly upon registration.

About ATH434

Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce a-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal

Wild

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

she will soon enough my friend! athe volume is about to warm up big time come end of summer all imo!

soo oversold its not even funny, also float is dang near locked, shorts will pay dearly soon enough!!! athe!

more news should be coming in the next 2/3 months, add to your watch list and start scaling in!

remember folks, this ran hard around this time last year, news will see us in the 3/4 $ range now with the many potential developments that lie ahead, I've added close to 100k shares here last few days.

building myself a nice little position here folks! cant beat the current price!

From the sticky...



Alterity’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of a-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical Parkinsonism.


A more practical solution may be enabling natural autophagy, which AVXL Blarcamesine seems to do....

"reduce abnormal accumulation" via iron balance seems to be a step lower than that.

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s
https://alteritytherapeutics.com/investor-centre/news/2022/01/06/alterity-therapeutics-granted-new-us-patent-for-compounds-for-neurodegenerative-diseases-including-parkinsons-and-alzheimers/

Roar!

28 thousand revenues VS. over 70 million Market Cap. Only a study and phase 2... Many more to go and more money to be spent

$0.00 revenue per share and burning over $22,000,000 million on the regular

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -56,493.91%...........

Management Effectiveness
Return on Assets (ttm) -38.31%
Return on Equity (ttm) -71.91%

Income Statement
Revenue (ttm) 28.15k
Revenue Per Share (ttm) 0.00
Quarterly Revenue Growth (yoy) 1.50%
Gross Profit (ttm) -352.92k
EBITDA -15.88M
Net Income Avi to Common (ttm) -16.38M
Diluted EPS (ttm) -0.6600

Cash Flow Statement
Operating Cash Flow (ttm) -14.18M
Levered Free Cash Flow (ttm) -8.64M

ATHE released news hasnt hit wires gap watch tomorrow ~> https://alteritytherapeutics.com/investor-centre/news/2021/07/15/new-publication-demonstrates-ath434-is-neuroprotective/

Chart -- ATHE

Testing the waters here. Close looked interesting. Maybe more upswing here tomorrow?

Added 2.08!

Wow float is locked

Look again

Off a patent? Nah

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and

Looking like we got a RUNNER

I think many of US are lurking this and when something starts to happen we shall all pop to share. Tiiick tooock...

* * $ATHE Video Chart 04-21-2021 * *

Link to Video - click here to watch the technical chart video

$ATHE is screaming for the top as investors point to the company's ability to treat Parkinsonian diseases on social media. This low float stock could go far higher. https://cnafinance.com/alterity-therapeutics-athe-stock-is-rocketing-heres-why/

nobody home here but thought I'd post anyways. Back in recently with a starter of 1.62's. I believe this is the old prana (pran) which at one time had some nice big run ups. This can too :)

Vanderbilt university medical center is enrolling patients with MSA = Multiple System Astrophysics for Altering Therapeutics limited phase 2 clinical studies using ATH434 to treat patients with MSA Neurodegenerative disease. The patient enrollment started in October 2020. Vanderbilt Medical Center is one of the top 10 medical school university in the USA. Vanderbilt Medical center enroll millions of patients for clinical trial testing for company drug testing. The University has an excellent reputation for screaming patients for clinical trial studies and testing.

Looking forward to the company addressing the share holders tomorrow. Will love to see a big spike in share price during pre market